Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: COVID-19

In brief

Study of ANA001 in Moderate and Severe COVID-19 Patients

Key facts

Study ID

NCT04603924

Run by

NeuroBo Pharmaceuticals Inc.

People needed

49

Starts

2020-10-07

Expected to finish

2022-02-16

Last updated by the study team

2025-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Helen Keller Hospital — Sheffield, Alabama, United States
• University of California, Irvine — Irvine, California, United States
• Baptist Health Research Institute — Jacksonville, Florida, United States
• AdventHealth Tampa — Tampa, Florida, United States
• University of Missouri Health Care — Columbia, Missouri, United States
• Caroline Institute for Clinical Research — Fayetteville, North Carolina, United States
• Memorial Hermann Memorial City Medical Center — Houston, Texas, United States
• Providence Regional Medical Center Everett — Everett, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.